CN112063621B - 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用 - Google Patents

杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用 Download PDF

Info

Publication number
CN112063621B
CN112063621B CN202010909759.7A CN202010909759A CN112063621B CN 112063621 B CN112063621 B CN 112063621B CN 202010909759 A CN202010909759 A CN 202010909759A CN 112063621 B CN112063621 B CN 112063621B
Authority
CN
China
Prior art keywords
lys
leu
glu
dmd
sgrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010909759.7A
Other languages
English (en)
Other versions
CN112063621A (zh
Inventor
常兴
李甲
邱晗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Westlake University
Original Assignee
Westlake University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202210530367.9A priority Critical patent/CN115011598A/zh
Application filed by Westlake University filed Critical Westlake University
Priority to CN202010909759.7A priority patent/CN112063621B/zh
Priority to PCT/CN2020/119361 priority patent/WO2022047876A1/zh
Priority to EP20952118.6A priority patent/EP4209590A1/en
Priority to JP2023515078A priority patent/JP2023540555A/ja
Priority to US18/043,874 priority patent/US20230287419A1/en
Priority to CA3191505A priority patent/CA3191505A1/en
Publication of CN112063621A publication Critical patent/CN112063621A/zh
Application granted granted Critical
Publication of CN112063621B publication Critical patent/CN112063621B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707Muscular dystrophy
    • C07K14/4708Duchenne dystrophy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005Cytidine deaminase (3.5.4.5)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Abstract

本发明公开了一种杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用。相关的外显子剪接增强子、sgRNA和基因编辑工具可在制备治疗杜氏肌营养不良症的药物中应用。其中,基于胞嘧啶脱氨酶AID的突变体与Cas9突变体设计的基因编辑工具,以腺相关病毒AAV为载体,可对哺乳动物的基因组进行定点改造。本发明通过优化编辑工具的编码核酸序列以及元件组成结构,可以高效实现哺乳动物遗传物质DNA的定点靶向改造,通过对携带疾病突变的核酸序列进行靶向遗传操作,使其致病突变无法保留至成熟的蛋白质氨基酸序列中或使致病突变无法发挥其功能,从而达到治疗多种基因突变类遗传性罕见病的目的,具有高效,安全,稳定的优点。

Description

杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编 辑工具及应用
技术领域
本发明属于基因治疗领域,涉及一种杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具在哺乳动物(实验动物模型以及人类病人)体内针对基因突变型遗传性疾病致病突变的改造治疗。尤其涉及杜氏肌营养不良症DMD在小鼠模型以及人类病人的基因编辑治疗。
背景技术
根据世界卫生组织WHO的定义,罕见病为在一定区域内,患病人数占总人口数0.065%~0.1%的非常见疾病。这类疾病往往发病机制难寻,缺少针对性治疗药物,对病人身体健康带来极大的危害,对其家庭以及社会均带来了极大的负担。由于我国极高的人口基数,罕见病发病的绝对数量不容忽视,近年来也引起了科研人员与临床专家的重视和关注。2018年5 月,我国国家卫生健康委员会、科技部、工业和信息化部、国家药品监督管理局、国家中医药管理局等五部门联合发布了《第一批罕见病》目录,其中列出了121种疾病,这也标志着罕见病在我国得到了进一步的重视和关注。
罕见病的发病机制往往是由于基因突变,造成复杂的多种临床疾病表现。限于诊断手段的局限性,病人在病程早期表现出临床症状后被笼统归为单一性疾病,经过长期治疗并没有得到改善后,才会被进一步判断为疑难未诊断疾病。因此,对于疑难未诊断疾病/罕见病的相关研究亟待开展,包括但不限于:致病机制的探究、诊断手段的优化、发病进程的追踪、药物靶点的筛选以及结合基因编辑技术对针对性基因药物的开发等;同时对特殊罕见病动物模型的发现和改良,也可以提高我们对罕见疾病的全方位理解和针对性药物的创新。本发明以肌营养不良症(Muscular Dystrophy)这一临床上发现较早却长期缺失有效治疗手段的罕见病为切入点,以杜氏肌营养不良症(Duchenne Muscular Dystrophy,DMD)为研究对象,结合新发现的小鼠模型,对该疾病的基因治疗手段进行了开发和优化,并将基因治疗手段应用于人类基因组序列中。
杜氏肌营养不良症DMD是一种X染色体遗传性疾病,大约每4000个新生男性中可以检测出一个患儿,其致病原因在于肌营养不良蛋白Dystrophin因基因突变而造成的表达缺失。对于DMD病人而言,心肌的组织损伤与功能异常是最致命的威胁。在很长的一段时间内,DMD 并没有十分有效的治疗手段,临床能够给予的治疗仅限于对症状的缓解:比如利用血管紧张素抑制剂来缓解心肌功能退化所带来的不适,这类药物包括配哚普利、以及多种洛尔类beta 受体阻断剂。同时,随着医疗手段的提高,介入治疗也帮助缓解DMD病人的症状,这其中包括心脏循环辅助系统和呼吸辅助系统等。但是,这些治疗并无法本质性地提高DMD病人的生活质量,延长DMD病人的寿命,心脏功能的进行性退化仍旧是DMD病人致死的最主要原因。随着分子生物学的不断进展,结合临床的数据分析,人们发现有一类同样在Dystrophin 蛋白的编码基因中存在突变的病人,并没有表现出与DMD病人一样的严重病理进程,这类病人被称为贝氏肌营养不良症BMD患者,他们所携带的Dystrophin基因突变不会造成完整蛋白open reading frame的破坏,因此可以产生具有一定生物学功能的Dystrophin蛋白,不会表现出严重的心肌功能障碍以及其他肌肉功能的缺陷。相对于DMD病人的严重病理进程, BMD病人的寿命不会得到明显的影响,可以几乎恢复如正常人一般的日常生活。这类BMD 病人的出现给了科研人员一个启发,是否可以在不影响蛋白读码框的前提下,诱导DMD病人中携带突变的外显子发生跳读,从而产生一种接近全长的Dystrophin蛋白,用于治疗DMD 病人。这种想法在近些年已经被付诸实践,现在已有多种携带突变的Exon可以被利用这种方案进行治疗,其中几类已经被批准开启临床实验。截止到2019年底,在全球范围内仅有有限的几种针对DMD的特效药物被批准上市。其中,SareptaTherapeutics是一家专注于开发精准基因疗法治疗罕见性疾病的生物技术公司。其研发的Golodirsen经美国FDA加速批准于2019 年12月12日上市,用于治疗确诊为发生53外显子跳跃基因突变的DMD患者。据估计,约 8%的DMD患者携带此突变。Golodirsen的本质是一种反义寡核苷酸,通过靶向肌营养不良蛋白的序列而发挥作用。因此,对其他突变位点设计的药物,在目前来说仍是一个极大的空白。目前来说,在全球范围内,包含已经进入临床试验的DMD针对性药物在内,竞争较为激烈,但需求依然巨大。目前针对DMD的药物据统计有5款上市药物,6款药物处在临床 III期试验阶段,19款药物处在临床II期阶段,还有5款药物刚刚进入临床I期试验阶段。需要指出的是,在人类DMD病人中,这些药物只适用于携带某种特定突变的一类病人,对于其他DMD病人来说,仍然缺少足够的针对性治疗药物。由SareptaTherapeutics研发的 Eteplirsen是一种反义二胺吗啉代寡核苷酸(PMO)治疗剂,是该公司首款治疗DMD的上市 (2016年)药物。然而这些目前已经上市的药物往往存在治疗效率低,需要持续给药,价格极其昂贵的缺点。而基因编辑治疗方案则是可以直接对基因突变型遗传病的致病突变进行靶向改造,一旦经过编辑,即可从根本上达到治愈疾病的效果,具有极大的优势。
不仅是DMD这一类疾病,目前在全球范围内,利用基因编辑工具针对罕见性遗传病治疗的应用极其罕见。
发明内容
本发明的目的在于针对基因突变型遗传性罕见病,提供一种杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具,作为药物用以哺乳动物(疾病动物模型以及人类病人)体内基因编辑治疗。
第一方面,本发明提供了一种杜氏肌营养不良症相关的外显子剪接增强子,所述外显子剪接增强子为靶向人类DMD基因Exon51的外显子剪接增强子元件,其核苷酸序列包括:
1)如SEQ ID N0.21所示的序列及其反向互补序列。
2)如SEQ ID N0.22所示的序列及其反向互补序列。
3)如SEQ ID N0.23所示的序列及其反向互补序列。
4)如SEQ ID N0.24所示的序列及其反向互补序列。
通过改变或者阻断上述外显子剪接增强子(Exon Splicing Enhancer,ESE)等元件,可以诱导跳读DMD基因Exon51,从而实现对哺乳动物体内基因编辑治疗。例如:CRISPRnuclease, 可以通过DNA的双链断裂引入的缺失插入片段(Insertions and deletions,Indels)破坏ESE的结构;反义寡聚核苷酸ASO,通过在细胞中靶向pre-mRNA的对应元件位置,阻止其保留至最终的蛋白质氨基酸序列中。
第二方面,本发明还提供了一种杜氏肌营养不良症相关的可以靶向特定基因组的单链向导RNA(single-strand guide RNA,sgRNA),所述sgRNA的序列包括:
针对Dmd-E4小鼠突变位点的sgRNA,其核苷酸序列如SEQ ID N0.4所示。
针对人类DMD基因Exon50的sgRNA,其核苷酸序列如SEQ ID N0.7所示。
针对人类DMD基因Exon51的sgRNA-1,其核苷酸序列如SEQ ID N0.8所示。
针对人类DMD基因Exon51的sgRNA-2,其核苷酸序列如SEQ ID N0.9所示。
针对人类DMD基因Exon51的sgRNA-3,其核苷酸序列如SEQ ID N0.10所示。
针对人类DMD基因Exon51的sgRNA-4,其核苷酸序列如SEQ ID N0.11所示。
针对人类DMD基因Exon51的sgRNA-5,其核苷酸序列如SEQ ID N0.12所示。
针对人类DMD基因Exon51的sgRNA-6,其核苷酸序列如SEQ ID N0.13所示。
针对人类DMD基因Exon51的sgRNA-7,其核苷酸序列如SEQ ID N0.14所示。
针对人类DMD基因Exon51的sgRNA-8,其核苷酸序列如SEQ ID N0.15所示。
针对人类DMD基因Exon51的sgRNA-9,其核苷酸序列如SEQ ID N0.16所示。
针对人类DMD基因Exon51的sgRNA-10,其核苷酸序列如SEQ ID N0.17所示。
针对人类DMD基因Exon51的sgRNA-11,其核苷酸序列如SEQ ID N0.18所示。
针对人类DMD基因Exon51的sgRNA-12,其核苷酸序列如SEQ ID N0.19所示。
针对人类DMD基因Exon51的sgRNA-13,其核苷酸序列如SEQ ID N0.20所示。
所述sgRNA与基因编辑工具结合,可在制备治疗杜氏肌营养不良症的药物中应用。
第三方面,本发明还提供了一种杜氏肌营养不良症相关的基因编辑工具,包括胞嘧啶脱氨酶和Cas9突变体的融合蛋白、权利要求2所述sgRNA和载体。所述载体为常用的生物质粒,例如AAV载体质粒、pCDNA3.1质粒等。
进一步地,胞嘧啶脱氨酶可以为AID、apobec等,作为优选,胞嘧啶脱氨酶为AID,AID 和Cas9突变体的融合蛋白的氨基酸序列以及核酸序列分别如SEQ ID NO.1和SEQ IDNO.2 所示。
进一步地,所述基因编辑工具由腺相关病毒载体AAV包装。腺相关病毒AAV可以将表达AID-Cas9融合蛋白以及sgRNA的核酸序列递送至靶细胞中,使其在细胞中表达出具有DNA编辑功能的蛋白质和具有引导功能的sgRNA分子,其中sgRNA可以引导AID-Cas9融合蛋白至靶细胞中的特定基因组位点,对致病突变进行诱导改造,使其失活以达到治疗疾病的目的。
进一步地,所述腺相关病毒载体AAV的启动子为Syn100启动子或基于ck8a、mhck7等设计的启动子。
进一步地,腺相关病毒载体AAV的核苷酸序列如SEQ ID NO.3所示。
本发明还提供了上述基因编辑工具在制备治疗杜氏肌营养不良症的药物中的应用。
本发明的有益效果是:
本发明以DMD小鼠模型和人类DMD病人携带的致病突变为例,通过设计构建基因编辑工具,利用腺相关病毒AAV在体内水平实现了对DMD小鼠模型的治疗;同时也针对人类DMD病人的致病突变,设计了基因编辑方案,在细胞水平实现了对致病突变的改造。本发明提供了对基因突变型遗传性罕见病的创新型治疗手段,有望对诸多遗传性罕见病实现突破性的治疗效果。
附图说明
图1为包含基因编辑工具的功能元件组成,其中,A为分开包毒、B为合并包毒;
图2为针对新型DMD小鼠疾病模型Dmd-E4治疗流程图,其中,A为新生小鼠预防性治疗、B为成年小鼠修复性治疗;
图3为AAV质粒的部分测序结果;A图为Syn100启动子的测序比对结果;B图为AID与Cas9突变体融合蛋白的测序比对结果;C图是U6启动子的测序比对结果。
图4.AAV治疗成功修复了Dmd-E4小鼠因Dystrophin表达缺陷所造成的疾病表型结果示意图,其中:A图,对经过治疗的Dmd-E4小鼠心脏中的RNA进行反转录PCR,引物设计在Exon3和Exon5中,检测携带突变的Exon4发生了跳读,Dmd为小鼠编码Dystrophin蛋白的基因,Gapdh为PCR的内参;B图,利用毛细管电泳定量的方法,确定Exon4发生跳读的条带与没有发生跳读(即包含)的条带所包含核酸量的比例;C图,对Exon4发生跳读的条带进行Sanger测序,确定Exon4发生了完整的跳读,Exon3和Exon5拼接到了一起;D图,对经过治疗的Dmd-E4小鼠心脏中的蛋白质进行免疫印迹检测,以WT小鼠以及没有经过治疗的小鼠样本为阳性与阴性对照,VCL为大分子量的内参;E图,D图中条带的定量统计;F 图,免疫荧光染色的方法检测经过治疗的Dmd-E4小鼠心脏中Dystrophin蛋白表达的情况,包括两个治疗后样本;G图,利用小动物心脏超声检测的方法考察Dmd-E4小鼠的心脏相关生理结构的改变在经过AAV治疗后是否得到了修复;H图,为F图的定量,量化了Dystrophin 阳性表达细胞的占比。P-value:*p<0.05,**p<0.01,***p<0.001.
图5.AAV治疗成功恢复了Dmd-E4小鼠的肌肉功能并延长了其生存期。A图,对经过治疗的Dmd-E4小鼠的血清中肌酸激酶含量进行了测定,WT与未经治疗的Dmd-E4小鼠样品为对照;B图,利用HE染色与Masson染色的方法,评估经过治疗后的Dmd-E4小鼠心肌炎症细胞浸润与纤维化的程度;C图,根据Masson染色的结果,定量统计经过治疗后的Dmd-E4 小鼠心肌纤维化程度的恢复情况;D图,利用micro-CT的方法,检测Dmd-E4小鼠脊柱弯曲的程度,以WT小鼠以及没有经过治疗的小鼠样本为对照;E图,D图中脊柱弯曲程度的定量统计;F图,利用拉力装置检测经过治疗的Dmd-E4小鼠全身肌肉最大拉力在循环发力过程中的降级幅度;G图,WT小鼠以及经过AAV治疗与未治疗的Dmd-E4小鼠的生存期统计; H图,Dmd-E4小鼠心肌细胞中基因编辑的分子生物学证据,将对应细胞的pre-mRNA进行逆转录PCR,后进行高通量测序,发现在sgRNA靶向的位置附近,产生了预期的突变,是对 Dmd-E4小鼠的心脏疾病表型进行治疗的分子基础与依据。*p<0.05,**p<0.01,***p<0.001。
图6.基因编辑工具在人类细胞中可以成功诱导DMD基因的对应改造。A图,在K562细胞系中成功筛选出两个sgRNA,可以诱导Exon51发生跳读,如图为编辑后的K562细胞抽提RNA后进行逆转录PCR的结果,显示两个sgRNA联用可以高效诱导缺失Exon50的K562 细胞成功跳读Exon51;B图,在正常人类iPS与缺失DMDExon50的细胞中诱导DMD基因的Exon51发生跳读;C图,利用免疫荧光检测的方法确定Dystrophin蛋白在经过编辑的iPS 细胞中回复了表达;D图,利用western blot的方法确定Dystrophin蛋白在经过编辑的iPS细胞中回复了表达;E图,D图中蛋白回复表达的定量统计。
具体实施方式
本发明以DMD小鼠模型和人类DMD病人携带的致病突变为例,通过设计构建基因编辑工具,实现了对致病突变的改造。下面结合具体实施例及附图对本发明作进一步说明:
实施例1携带基因编辑工具的AAV病毒
根据本发明设计的基因编辑工具如图1所示,以AID为例,我们将对应的序列克隆至 AAV质粒中,包括如下步骤:
首先,以XhoI和NotI的酶切位点为基础对pAAV2骨架载体(购自addgene,但不限于此)进行双酶切。同时设计基因编辑工具中AID和Cas9融合蛋白的氨基酸序列,氨基酸序列以及核酸序列分别如SEQ ID NO.1和SEQ ID NO.2所示。经过密码子优化后,直接合成双链DNA片段,与Syn100启动子以及加尾信号等元件连接至AAV骨架载体中获得表达 AID-Cas9突变体融合蛋白的AAV载体质粒,其序列SEQ ID NO.3所示。此外,利用引物合成以及PCR的方法,可以将U6启动子、H1启动子以及7SK启动子的序列与识别致病突变外显子剪切位点的sgRNA连接起来,同时用Syn100启动子与加尾信号来表达绿色荧光蛋白以及相关元件,以增加蛋白表达标签以及辅助提升基因编辑效率;此外,还可以采用合并包毒的AAV质粒构建基因编辑工具,在AID和Cas9融合蛋白表达元件的基础上,连接U6启动子与靶向致病突变外显子剪切位点的sgRNA,构建成为4.9kbp插入序列的AAV质粒载体。相关质粒克隆的部分结果如下图3所示。
在构建完成的AAV载体质粒后,根据既往文献[Grieger,J.,Choi,V.&Samulski,R.Production and characterization of adeno-associated viral vectors.Nat Protoc1,1412–1428(2006).],包装并纯化得到滴度为1x1013v.g./mL的血清型为AAV9的AAV病毒。分别包毒的按比例混合使用,合并包毒的可直接用于体内治疗;
实施例2利用携带基因编辑工具的AAV对DMD模型小鼠进行体内治疗
本实施例选择了一种具有心脏功能异常的新型DMD小鼠疾病模型Dmd-E4,该模型可购自江苏集萃药康生物科技有限公司,但不限于此。Dmd-E4在6-8周心脏即出现了心肌肥厚,纤维化等表型,而在8个月左右则表现出心脏功能的严重退化。这一过程很好地模拟了DMD 病人的心脏病理进程。针对这一模型,我们应用胞嘧啶脱氨酶与Cas9设计基因编辑工具,以携带致病突变的外显子为目标,在其5’剪接位点附近进行诱导突变,使其发生跳读,在不影响蛋白开放阅读框的基础上,最大限度地保留Dystrophin蛋白的表达,恢复其生物学功能。
具体地,采用实施例1的方法构建基因编辑工具,其中设计的针对Dmd-E4小鼠突变位点的sgRNA序列如SEQ ID NO.4所示,得到的表达针对Dmd-E4小鼠突变位点的sgRNA的AAV载体质粒,其序列如SEQ ID NO.5所示。包含AID-Cas9融合蛋白与针对Dmd-E4小鼠的sgRNA于同一AAV载体质粒的对应序列如SEQ ID NO.6所示。
选择血清型为AAV9的病毒合成与纯化,并按照新生小鼠的预防性治疗与成年小鼠的修复性治疗两种方案进行对Dmd-E4小鼠的治疗,如图2所示。
(A)新生小鼠的基因治疗
入组:将Dmd-E4小鼠纯和KO的雌雄小鼠交配,待雌鼠怀孕后,雌雄小鼠分笼,每隔两日观察怀孕雌鼠是否生产,待新生Dmd-E4小鼠出生后,观察性别,选取3-5只雄鼠作为实验组,另外3-5只雄鼠为阴性对照组;
给药:将50-75μL的携带基因编辑工具的腺相关病毒AAV(滴度1013v.g./mL)通过腹腔注射或者面静脉注射的方式给药,对照小鼠同时给予等体积的无菌PBS,随后与母鼠一起正常饲养;
采样和检测:待小鼠成长至2个月左右时,除实验组与对照组外,取3-5只同龄WT雄鼠,同时进行如下处理:麻醉小鼠后,首先进行胫骨前肌的功能测试、超声心动图的检测等,随后采集心脏动静脉血以处死小鼠,离心分离血清后存于-80℃,同时收集心肌、骨骼肌、胫骨前肌、背部肌肉、肝脏、脑部、肾脏等组织,并提取其蛋白质、RNA、基因组DNA,以及留存足够组织进行免疫荧光染色、苏木精伊红染色等。
如图4A所示,对经过治疗的Dmd-E4小鼠心脏中的RNA进行反转录PCR,引物设计在Exon3和Exon5中,检测携带突变的Exon4发生了跳读;同时,利用毛细管电泳定量的方法,确定Exon4发生跳读的条带与没有发生跳读(即包含)的条带所包含核酸量的比例;结果如图4B所示。进一步地,对Exon4发生跳读的条带进行Sanger测序,如图4C所示,Exon4 发生了完整的跳读,Exon3和Exon5拼接到了一起;图4 D-F是对小鼠心脏中的蛋白质进行免疫印迹检测,其中,图4D是条带图,图4 E是4 D图中条带的定量统计,图4F Dystrophin蛋白表达的情况,结果表明经过治疗的Dmd-E4显著恢复了Dystrophin蛋白表达。另外,利用小动物心脏超声检测的方法考察Dmd-E4小鼠的心脏相关生理结构的改变在经过AAV治疗后是否得到了修复。结果图4G所示,结果表明治疗后Dmd-E4小鼠的心脏相关生理结构基本得到修复。
进一步地,对Dmd-E4小鼠的肌肉功能及其生存期是否恢复及延长进行了验证。图5A 是小鼠的血清中肌酸激酶含量测定结果,从图中可以看出,与WT和未经治疗的Dmd-E4小鼠样品相比,治疗后的Dmd-E4小鼠肌酸激酶含量显著下降。利用HE染色与Masson染色的方法,评估经过治疗后的Dmd-E4小鼠心肌炎症细胞浸润与纤维化的程度,同时根据Masson 染色的结果,定量统计经过治疗后的Dmd-E4小鼠心肌纤维化程度的恢复情况,结果如图 5B-5C所示,治疗后的Dmd-E4小鼠心肌纤维化程度明显得到了改善。另外,还利用micro-CT 的方法,检测Dmd-E4小鼠脊柱弯曲的程度(图5D-5E),利用拉力装置检测经过治疗的Dmd-E4小鼠全身肌肉最大拉力在循环发力过程中的降级幅度(图5F),结果均表明Dmd-E4小鼠在经过治疗后,脊柱的弯曲程度得到了缓解,同时小鼠的全身肌肉拉力得到了增强,并且极大地延长了Dmd-E4小鼠的生存期(图5G)。图5H为Dmd-E4小鼠心肌细胞中基因编辑的分子生物学证据,将对应细胞的pre-mRNA进行逆转录PCR,后进行高通量测序,发现在sgRNA 靶向的位置附近,产生了预期的突变,是对Dmd-E4小鼠的心脏疾病表型进行治疗的分子基础与依据。
上述结果表明,本发明的基因编辑工具能够有效治疗和预防新生Dmd-E4小鼠。
(B)成年小鼠的基因治疗
入组:取3-5只4-6周龄的纯和KO Dmd-E4雄鼠作为实验组给予基因治疗,取3-5只4-6 周龄的纯和KO Dmd-E4雄鼠作为对照组给予等量PBS处理;
给药:将约50μL的携带基因编辑工具的腺相关病毒AAV(滴度1013v.g./mL)通过尾静脉注射或骨骼肌原位注射的方式给药,对照小鼠同时给予等体积的无菌PBS;
采样和检测:待小鼠经过治疗后2个月左右时,除实验组与对照组外,取3-5只同龄WT 雄鼠,同时进行如下处理:麻醉小鼠后,首先进行胫骨前肌的功能测试、超声心动图的检测等,随后采集心脏动静脉血以处死小鼠,离心分离血清后存于-80℃,同时收集心肌、骨骼肌、胫骨前肌、背部肌肉、肝脏、脑部、肾脏等组织,并提取其蛋白质、RNA、基因组DNA,以及留存足够组织进行免疫荧光染色、苏木精伊红染色等。
结果表明:通过AAV作为基因编辑工具的运载介质,可以实现对突变外显子的高效基因修复。在经过治疗的Dmd-E4小鼠中,心肌及多个肌肉组织中均可以观察到致病外显子发生了跳读,并因此恢复了Dystrophin蛋白的表达,同时心肌损伤的表型也得到了明显的修复,使成年Dmd-E4小鼠得到了治疗。
实施例3对人类诱导多能干细胞iPSC的DMD模型进行基因编辑成功恢复Dystrophin蛋白的表达
本发明同时对人类细胞的基因编辑治疗进行了成功的实施。首先我们从正常人外周血单核细胞中构建了诱导多能干细胞(iPSC),随后利用CRISPR-cas9的方法特异性地删除了 Dystrophin编码基因DMD的第50号外显子Exon50,使得Dystrophin蛋白的编码序列产生了移码突变,从而构建了模拟DMD病人的突变类型,成为一个很好的DMD疾病模型细胞。针对此细胞,我们设计了AID和Cas9融合蛋白与对应的sgRNA的序列,用于靶向DMD基因的第51号外显子Exon51的一系列潜在调控外显子剪接的元件,本实施例中采用的sgRNA 为如SEQID No.19所示的sgRNA-12和如SEQ ID No.20所示的sgRNA-13,sgRNA-12主要靶向如SEQ IDN0.21、SEQ ID N0.22所示的外显子剪接增强子。sgRNA-13主要靶向如SEQ ID N0.24所示的外显子剪接增强子。上述两个sgRNA-12在人类K562细胞系中筛选获得,可以诱导Exon51的跳读,如图6A所示,编辑后的K562细胞抽提RNA后进行逆转录PCR的结果,显示两个sgRNA均能诱导突变,联用可以高效诱导缺失Exon50的K562细胞成功跳读 Exon51。同时通过诱导Exon51的跳读,可以使缺失Exon50的iPS细胞中Dystrophin蛋白的开放阅读框恢复,进而重建Dystrophin蛋白的表达。具体实施方案如下:
3.1诱导iPS细胞向心肌细胞分化
(1)用Accutase消化培养在基质胶上的人iPS细胞,37℃消化6分钟,用DMEM培养基终止反应,收集细胞,1500rpm离心3分钟,并在显微镜下计数;
(2)将iPS细胞铺在预先用基质胶包被过的12孔板中,调整细胞密度为10000-20000细胞/cm2,iPS细胞用mTeSR1培养基培养,并加入10μM ROCK抑制剂(Y-27632),培养4天,每天更换新鲜培养基,更换培养基时不需要添加ROCK抑制剂;
(3)细胞培养4天后,将mTeSR1培养基更换为含有6uM CHIR99021的RPMI/B27-insulin 培养基,培养2天;
(4)撤去CHIR99021刺激,将培养基更换为RPMI/B27-insulin培养基,培养1天;
(5)将培养基更换为含有5μM IWR1的RPMI/B27-insulin培养基,培养2天;
(6)撤去IWR1刺激,将培养基更换为RPMI/B27-insulin培养基,培养2天;
将细胞培养基更换为RPMI/B27培养基,之后一直用此培养基培养,每两天换一次培养基,获得向心肌细胞分化的人多能干细胞。
3.2在向心肌细胞诱导分化的人多能干细胞中进行基因编辑工具的转染
(1)在转染前一天,用Accutase消化向心肌细胞分化的iPS细胞,铺于6孔板中,每孔中铺4×105细胞;
(2)约24h后等到向心肌细胞分化的iPS细胞密度达到60%左右时,将细胞培养基换成无抗培养基;
(3)将2.5μg表达AID与Cas9突变体融合蛋白的质粒(例如Lenti-V2-AIDx-nSaCas9(KKH)-Ugi质粒)与500ng表达UGI的质粒(例如pCDNA3.1-Ugi)质粒以及1.5μg sgRNA 质粒混匀在150μl opti-MEM中,并加入2.5μl PLUSTM试剂,轻轻混匀;
(4)将12μl Lipofectamine LTX与150μl opti-MEM培养基混匀,并将其加入到步骤(3) 的质粒中,轻轻混匀,室温孵育15min,将反应产物加入到(2)的向心肌细胞分化的iPS细胞中;
(5)转染48h后,在转染的细胞中加入2μg/ml puromycin,筛选3天后撤药,转染后7天收取细胞进行分析。
3.3对经过编辑的iPSC进行相关指标的检测
(1)抽提编辑前后iPSC的基因组DNA,检测相应的Exon51是否发生了突变;
(2)抽提编辑前后iPSC的RNA,进行逆转录PCR,检测Exon51在RNA水平上是否发生了跳读,结果如图6B所示,在正常人类iPS与缺失DMD Exon50的细胞中诱导DMD基因的Exon51发生跳读;
(3)对编辑前后iPSC在蛋白水平上考察Dystrophin蛋白的表达,实验方法包括Western Blot,免疫荧光染色等。图6C是利用免疫荧光检测的方法确定Dystrophin蛋白在经过编辑的 iPS细胞中恢复了表达的结果;图6D是利用western blot的方法确定Dystrophin蛋白在经过编辑的iPS细胞中恢复了表达;图6E是D图中蛋白回复表达的定量统计;
上述结果表明:在K562细胞系中成功构建出可以诱导人类DMD基因Exon51等发生跳读的基因编辑方式,鉴定出一系列潜在调控外显子跳读的序列元件,同时进一步利用这种基因编辑方案,可以将DMD疾病模型细胞iPSC成功进行治疗性改造,恢复Dystrophin蛋白的表达。
另外,其余SEQ ID No.7-SEQ ID No.18所示的sgRNA-1~sgRNA-11均是靶向本发明对应的如SEQ ID No.21-SEQ ID No.24所示的外显子剪接增强子,当采用其构建成基因编辑工具时,高效诱导跳读Exon51,从而实现治疗人类DMD。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其他不同形式的变化或变动。这里无需也无法把所有的实施方式予以穷举。而由此所引申出的显而易见的变化或变动仍处于本发明的保护范围。
序列表
<110> 西湖大学
<120> 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用
<160> 24
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1420
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Met Asp Tyr Lys Asp His Asp Gly Asp Tyr Lys Asp His Asp Ile Asp
1 5 10 15
Tyr Lys Asp Asp Asp Asp Lys Met Ala Pro Lys Lys Lys Arg Lys Val
20 25 30
Gly Ile His Gly Val Pro Ala Ala Met Asp Ser Leu Leu Met Asn Arg
35 40 45
Arg Glu Phe Leu Tyr Gln Phe Lys Asn Val Arg Trp Ala Lys Gly Arg
50 55 60
Arg Glu Thr Tyr Leu Cys Tyr Val Val Lys Arg Arg Asp Ser Ala Thr
65 70 75 80
Ser Phe Ser Leu Asp Phe Gly Tyr Leu Arg Asn Lys Asn Gly Cys His
85 90 95
Val Glu Leu Leu Phe Leu Arg Tyr Ile Ser Asp Trp Asp Leu Asp Pro
100 105 110
Gly Arg Cys Tyr Arg Val Thr Trp Phe Ile Ser Trp Ser Pro Cys Tyr
115 120 125
Asp Cys Ala Arg His Val Ala Asp Phe Leu Arg Gly Asn Pro Asn Leu
130 135 140
Ser Leu Arg Ile Phe Thr Ala Arg Leu Tyr Phe Cys Glu Asp Arg Lys
145 150 155 160
Ala Glu Pro Glu Gly Leu Arg Arg Leu His Arg Ala Gly Val Gln Ile
165 170 175
Ala Ile Met Thr Phe Lys Asp Tyr Phe Tyr Cys Trp Asn Thr Phe Val
180 185 190
Glu Asn His Gly Arg Thr Phe Lys Ala Trp Glu Gly Leu His Glu Asn
195 200 205
Ser Val Arg Leu Ser Arg Gln Leu Arg Arg Ile Leu Leu Pro Ser Gly
210 215 220
Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser Gly Lys
225 230 235 240
Arg Asn Tyr Ile Leu Gly Leu Ala Ile Gly Ile Thr Ser Val Gly Tyr
245 250 255
Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly Val Arg
260 265 270
Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg Ser Lys
275 280 285
Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile Gln Arg
290 295 300
Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His Ser Glu
305 310 315 320
Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu Ser Gln
325 330 335
Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu Ala Lys
340 345 350
Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr Gly Asn
355 360 365
Glu Leu Ser Thr Lys Glu Gln Ile Ser Arg Asn Ser Lys Ala Leu Glu
370 375 380
Glu Lys Tyr Val Ala Glu Leu Gln Leu Glu Arg Leu Lys Lys Asp Gly
385 390 395 400
Glu Val Arg Gly Ser Ile Asn Arg Phe Lys Thr Ser Asp Tyr Val Lys
405 410 415
Glu Ala Lys Gln Leu Leu Lys Val Gln Lys Ala Tyr His Gln Leu Asp
420 425 430
Gln Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg Arg Thr
435 440 445
Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp Lys Asp Ile
450 455 460
Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe Pro Glu
465 470 475 480
Glu Leu Arg Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr Asn Ala
485 490 495
Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn Glu Lys
500 505 510
Leu Glu Tyr Tyr Glu Lys Phe Gln Ile Ile Glu Asn Val Phe Lys Gln
515 520 525
Lys Lys Lys Pro Thr Leu Lys Gln Ile Ala Lys Glu Ile Leu Val Asn
530 535 540
Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys Pro Glu
545 550 555 560
Phe Thr Asn Leu Lys Val Tyr His Asp Ile Lys Asp Ile Thr Ala Arg
565 570 575
Lys Glu Ile Ile Glu Asn Ala Glu Leu Leu Asp Gln Ile Ala Lys Ile
580 585 590
Leu Thr Ile Tyr Gln Ser Ser Glu Asp Ile Gln Glu Glu Leu Thr Asn
595 600 605
Leu Asn Ser Glu Leu Thr Gln Glu Glu Ile Glu Gln Ile Ser Asn Leu
610 615 620
Lys Gly Tyr Thr Gly Thr His Asn Leu Ser Leu Lys Ala Ile Asn Leu
625 630 635 640
Ile Leu Asp Glu Leu Trp His Thr Asn Asp Asn Gln Ile Ala Ile Phe
645 650 655
Asn Arg Leu Lys Leu Val Pro Lys Lys Val Asp Leu Ser Gln Gln Lys
660 665 670
Glu Ile Pro Thr Thr Leu Val Asp Asp Phe Ile Leu Ser Pro Val Val
675 680 685
Lys Arg Ser Phe Ile Gln Ser Ile Lys Val Ile Asn Ala Ile Ile Lys
690 695 700
Lys Tyr Gly Leu Pro Asn Asp Ile Ile Ile Glu Leu Ala Arg Glu Lys
705 710 715 720
Asn Ser Lys Asp Ala Gln Lys Met Ile Asn Glu Met Gln Lys Arg Asn
725 730 735
Arg Gln Thr Asn Glu Arg Ile Glu Glu Ile Ile Arg Thr Thr Gly Lys
740 745 750
Glu Asn Ala Lys Tyr Leu Ile Glu Lys Ile Lys Leu His Asp Met Gln
755 760 765
Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu Glu Asp Leu
770 775 780
Leu Asn Asn Pro Phe Asn Tyr Glu Val Asp His Ile Ile Pro Arg Ser
785 790 795 800
Val Ser Phe Asp Asn Ser Phe Asn Asn Lys Val Leu Val Lys Gln Glu
805 810 815
Glu Asn Ser Lys Lys Gly Asn Arg Thr Pro Phe Gln Tyr Leu Ser Ser
820 825 830
Ser Asp Ser Lys Ile Ser Tyr Glu Thr Phe Lys Lys His Ile Leu Asn
835 840 845
Leu Ala Lys Gly Lys Gly Arg Ile Ser Lys Thr Lys Lys Glu Tyr Leu
850 855 860
Leu Glu Glu Arg Asp Ile Asn Arg Phe Ser Val Gln Lys Asp Phe Ile
865 870 875 880
Asn Arg Asn Leu Val Asp Thr Arg Tyr Ala Thr Arg Gly Leu Met Asn
885 890 895
Leu Leu Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys Val Lys
900 905 910
Ser Ile Asn Gly Gly Phe Thr Ser Phe Leu Arg Arg Lys Trp Lys Phe
915 920 925
Lys Lys Glu Arg Asn Lys Gly Tyr Lys His His Ala Glu Asp Ala Leu
930 935 940
Ile Ile Ala Asn Ala Asp Phe Ile Phe Lys Glu Trp Lys Lys Leu Asp
945 950 955 960
Lys Ala Lys Lys Val Met Glu Asn Gln Met Phe Glu Glu Lys Gln Ala
965 970 975
Glu Ser Met Pro Glu Ile Glu Thr Glu Gln Glu Tyr Lys Glu Ile Phe
980 985 990
Ile Thr Pro His Gln Ile Lys His Ile Lys Asp Phe Lys Asp Tyr Lys
995 1000 1005
Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Lys Leu Ile Asn Asp
1010 1015 1020
Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr Leu Ile Val
1025 1030 1035 1040
Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu Lys Lys
1045 1050 1055
Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His Asp Pro
1060 1065 1070
Gln Thr Tyr Gln Lys Leu Lys Leu Ile Met Glu Gln Tyr Gly Asp Glu
1075 1080 1085
Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr Leu Thr
1090 1095 1100
Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile Lys Tyr
1105 1110 1115 1120
Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp Tyr Pro
1125 1130 1135
Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr Arg Phe
1140 1145 1150
Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val Lys Asn
1155 1160 1165
Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser Lys Cys
1170 1175 1180
Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala Glu Phe
1185 1190 1195 1200
Ile Ala Ser Phe Tyr Lys Asn Asp Leu Ile Lys Ile Asn Gly Glu Leu
1205 1210 1215
Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile Glu Val
1220 1225 1230
Asn Met Ile Asp Ile Thr Tyr Arg Glu Tyr Leu Glu Asn Met Asn Asp
1235 1240 1245
Lys Arg Pro Pro His Ile Ile Lys Thr Ile Ala Ser Lys Thr Gln Ser
1250 1255 1260
Ile Lys Lys Tyr Ser Thr Asp Ile Leu Gly Asn Leu Tyr Glu Val Lys
1265 1270 1275 1280
Ser Lys Lys His Pro Gln Ile Ile Lys Lys Gly Gly Ser Ser Gly Gly
1285 1290 1295
Ser Thr Asn Leu Ser Asp Ile Ile Glu Lys Glu Thr Gly Lys Gln Leu
1300 1305 1310
Val Ile Gln Glu Ser Ile Leu Met Leu Pro Glu Glu Val Glu Glu Val
1315 1320 1325
Ile Gly Asn Lys Pro Glu Ser Asp Ile Leu Val His Thr Ala Tyr Asp
1330 1335 1340
Glu Ser Thr Asp Glu Asn Val Met Leu Leu Thr Ser Asp Ala Pro Glu
1345 1350 1355 1360
Tyr Lys Pro Trp Ala Leu Val Ile Gln Asp Ser Asn Gly Glu Asn Lys
1365 1370 1375
Ile Lys Met Leu Ser Gly Gly Ser Pro Lys Lys Lys Arg Lys Val Gly
1380 1385 1390
Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Tyr Pro Tyr Asp Val Pro
1395 1400 1405
Asp Tyr Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
1410 1415 1420
<210> 2
<211> 4263
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
atggactata aggaccacga cggagactac aaggatcatg atattgatta caaagacgat 60
gacgataaga tggccccaaa gaagaagcgg aaggtcggta tccacggagt cccagcagcc 120
atggacagcc tcttgatgaa ccggagggag tttctttacc aattcaaaaa tgtccgctgg 180
gctaagggtc ggcgtgagac ctacctgtgc tacgtagtga agaggcgtga cagtgctaca 240
tccttttcac tggactttgg ttatcttcgc aataagaacg gctgccacgt ggaattgctc 300
ttcctccgct acatctcgga ctgggaccta gaccctggcc gctgctaccg cgtcacctgg 360
ttcatctcct ggagcccctg ctacgactgt gcccgacatg tggccgactt tctgcgaggg 420
aaccccaacc tcagtctgag gatcttcacc gcgcgcctct acttctgtga ggaccgcaag 480
gctgagcccg aggggctgcg gcggctgcac cgcgccgggg tgcaaatagc catcatgacc 540
ttcaaagatt atttttactg ctggaatact tttgtagaaa accatggaag aactttcaaa 600
gcctgggaag ggctgcatga aaattcagtt cgtctatcca gacagcttcg gcgcatcctt 660
ttgcccagcg gcagcgagac tcccgggacc tcagagtccg ccacacccga aagcggcaag 720
aggaactaca tcctgggcct ggccatcggc atcaccagcg tgggctacgg catcatcgac 780
tacgagacca gggacgtgat cgacgccggc gtgaggctgt tcaaggaggc caacgtggag 840
aacaacgagg gcaggaggag caagaggggc gccaggaggc tgaagaggag gaggaggcac 900
aggatccaga gggtgaagaa gctgctgttc gactacaacc tgctgaccga ccacagcgag 960
ctgagcggca tcaaccctta cgaggccagg gtgaagggcc tgagccagaa gctgagcgag 1020
gaggagttca gcgccgccct gctgcacctg gccaagagga ggggcgtgca caacgtgaac 1080
gaggtggagg aggacaccgg caacgagctg agcaccaagg agcagatcag caggaacagc 1140
aaggccctgg aggagaagta cgtggccgag ctgcagctgg agaggctgaa gaaggacggc 1200
gaggtgaggg gcagcatcaa caggttcaag accagcgact acgtgaagga ggccaagcag 1260
ctgctgaagg tgcagaaggc ctaccaccag ctggaccaga gcttcatcga cacctacatc 1320
gacctgctgg agaccaggag gacctactac gagggccctg gcgagggcag ccctttcggc 1380
tggaaggaca tcaaggagtg gtacgagatg ctgatgggcc actgcaccta cttccctgag 1440
gagctgagga gcgtgaagta cgcctacaac gccgacctgt acaacgccct gaacgacctg 1500
aacaacctgg tgatcaccag ggacgagaac gagaagctgg agtactacga gaagttccag 1560
atcatcgaga acgtgttcaa gcagaagaag aagcctaccc tgaagcagat cgccaaggag 1620
atcctggtga acgaggagga catcaagggc tacagggtga ccagcaccgg caagcctgag 1680
ttcaccaacc tgaaggtgta ccacgacatc aaggacatca ccgccaggaa ggagatcatc 1740
gagaacgccg agctgctgga ccagatcgcc aagatcctga ccatctacca gagcagcgag 1800
gacatccagg aggagctgac caacctgaac agcgagctga cccaggagga gatcgagcag 1860
atcagcaacc tgaagggcta caccggcacc cacaacctga gcctgaaggc catcaacctg 1920
atcctggacg agctgtggca caccaacgac aaccagatcg ccatcttcaa caggctgaag 1980
ctggtgccta agaaggtgga cctgagccag cagaaggaga tccctaccac cctggtggac 2040
gacttcatcc tgagccctgt ggtgaagagg agcttcatcc agagcatcaa ggtgatcaac 2100
gccatcatca agaagtacgg cctgcctaac gacatcatca tcgagctggc cagggagaag 2160
aacagcaagg acgcccagaa gatgatcaac gagatgcaga agaggaacag gcagaccaac 2220
gagaggatcg aggagatcat caggaccacc ggcaaggaga acgccaagta cctgatcgag 2280
aagatcaagc tgcacgacat gcaggagggc aagtgcctgt acagcctgga ggccatccct 2340
ctggaggacc tgctgaacaa ccctttcaac tacgaggtgg accacatcat ccctaggagc 2400
gtgagcttcg acaacagctt caacaacaag gtgctggtga agcaggagga gaacagcaag 2460
aagggcaaca ggaccccttt ccagtacctg agcagcagcg acagcaagat cagctacgag 2520
accttcaaga agcacatcct gaacctggcc aagggcaagg gcaggatcag caagaccaag 2580
aaggagtacc tgctggagga gagggacatc aacaggttca gcgtgcagaa ggacttcatc 2640
aacaggaacc tggtggacac caggtacgcc accaggggcc tgatgaacct gctgaggagc 2700
tacttcaggg tgaacaacct ggacgtgaag gtgaagagca tcaacggcgg cttcaccagc 2760
ttcctgagga ggaagtggaa gttcaagaag gagaggaaca agggctacaa gcaccacgcc 2820
gaggacgccc tgatcatcgc caacgccgac ttcatcttca aggagtggaa gaagctggac 2880
aaggccaaga aggtgatgga gaaccagatg ttcgaggaga agcaggccga gagcatgcct 2940
gagatcgaga ccgagcagga gtacaaggag atcttcatca cccctcacca gatcaagcac 3000
atcaaggact tcaaggacta caagtacagc cacagggtgg acaagaagcc taacaggaag 3060
ctgatcaacg acaccctgta cagcaccagg aaggacgaca agggcaacac cctgatcgtg 3120
aacaacctga acggcctgta cgacaaggac aacgacaagc tgaagaagct gatcaacaag 3180
agccctgaga agctgctgat gtaccaccac gaccctcaga cctaccagaa gctgaagctg 3240
atcatggagc agtacggcga cgagaagaac cctctgtaca agtactacga ggagaccggc 3300
aactacctga ccaagtacag caagaaggac aacggccctg tgatcaagaa gatcaagtac 3360
tacggcaaca agctgaacgc ccacctggac atcaccgacg actaccctaa cagcaggaac 3420
aaggtggtga agctgagcct gaagccttac aggttcgacg tgtacctgga caacggcgtg 3480
tacaagttcg tgaccgtgaa gaacctggac gtgatcaaga aggagaacta ctacgaggtg 3540
aacagcaagt gctacgagga ggccaagaag ctgaagaaga tcagcaacca ggccgagttc 3600
atcgccagct tctacaagaa cgacctgatc aagatcaacg gcgagctgta cagggtgatc 3660
ggcgtgaaca acgacctgct gaacaggatc gaggtgaaca tgatcgacat cacctacagg 3720
gagtacctgg agaacatgaa cgacaagagg cctcctcaca tcatcaagac catcgccagc 3780
aagacccaga gcatcaagaa gtacagcacc gacatcctgg gcaacctgta cgaggtgaag 3840
agcaagaagc accctcagat catcaagaag ggcggcagca gcggcggcag caccaacctg 3900
agcgacatca tcgagaagga gaccggtaag caactggtta tccaggaatc catcctcatg 3960
ctcccagagg aggtggaaga agtcattggg aacaagccgg aaagcgatat actcgtgcac 4020
accgcctacg acgagagcac cgacgagaat gtcatgcttc tgactagcga cgcccctgaa 4080
tacaagcctt gggctctggt catacaggat agcaacggtg agaacaagat taagatgctc 4140
tctggtggtt ctcccaagaa gaagaggaaa gtcggatcct acccatacga tgttccagat 4200
tacgcttacc catacgatgt tccagattac gcttacccat acgatgttcc agattacgct 4260
taa 4263
<210> 3
<211> 7661
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg ggcgaccttt 60
ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa ctccatcact 120
aggggttcct gcggcctcta gactcgagcg gccgtccgcc ctcggcacca ttcctcacga 180
caccgaaata tggcgacggg tgaggaatgg tggggagtta tttttagagc ggtgaggaat 240
ggtgggcagg cagcaggtgt tgggggagtt atttttagag cggggagtta tttttagagc 300
ggtgaggaat ggtggacacc gaaatatggc gacgggtgag gaatggtgcc gtcgccatat 360
ttgggtgtcc cgtccgccct cggccggggc cgcattcctg ggggccgggc ggtgctcccg 420
cccgcctcga taaaaggctc cggggccggc ggcggcccac gagctacccg gaggagcggg 480
aggcgtctct gccagcggtc cgacgcgcag tcagcaccag gtaggtgggc accgcgccgt 540
gccgtgccgc tagctaatac gactcactat agggagagcc gccaccatgg actataagga 600
ccacgacgga gactacaagg atcatgatat tgattacaaa gacgatgacg ataagatggc 660
cccaaagaag aagcggaagg tcggtatcca cggagtccca gcagccatgg acagcctctt 720
gatgaaccgg agggagtttc tttaccaatt caaaaatgtc cgctgggcta agggtcggcg 780
tgagacctac ctgtgctacg tagtgaagag gcgtgacagt gctacatcct tttcactgga 840
ctttggttat cttcgcaata agaacggctg ccacgtggaa ttgctcttcc tccgctacat 900
ctcggactgg gacctagacc ctggccgctg ctaccgcgtc acctggttca tctcctggag 960
cccctgctac gactgtgccc gacatgtggc cgactttctg cgagggaacc ccaacctcag 1020
tctgaggatc ttcaccgcgc gcctctactt ctgtgaggac cgcaaggctg agcccgaggg 1080
gctgcggcgg ctgcaccgcg ccggggtgca aatagccatc atgaccttca aagattattt 1140
ttactgctgg aatacttttg tagaaaacca tggaagaact ttcaaagcct gggaagggct 1200
gcatgaaaat tcagttcgtc tatccagaca gcttcggcgc atccttttgc ccagcggcag 1260
cgagactccc gggacctcag agtccgccac acccgaaagc ggcaagagga actacatcct 1320
gggcctggcc atcggcatca ccagcgtggg ctacggcatc atcgactacg agaccaggga 1380
cgtgatcgac gccggcgtga ggctgttcaa ggaggccaac gtggagaaca acgagggcag 1440
gaggagcaag aggggcgcca ggaggctgaa gaggaggagg aggcacagga tccagagggt 1500
gaagaagctg ctgttcgact acaacctgct gaccgaccac agcgagctga gcggcatcaa 1560
cccttacgag gccagggtga agggcctgag ccagaagctg agcgaggagg agttcagcgc 1620
cgccctgctg cacctggcca agaggagggg cgtgcacaac gtgaacgagg tggaggagga 1680
caccggcaac gagctgagca ccaaggagca gatcagcagg aacagcaagg ccctggagga 1740
gaagtacgtg gccgagctgc agctggagag gctgaagaag gacggcgagg tgaggggcag 1800
catcaacagg ttcaagacca gcgactacgt gaaggaggcc aagcagctgc tgaaggtgca 1860
gaaggcctac caccagctgg accagagctt catcgacacc tacatcgacc tgctggagac 1920
caggaggacc tactacgagg gccctggcga gggcagccct ttcggctgga aggacatcaa 1980
ggagtggtac gagatgctga tgggccactg cacctacttc cctgaggagc tgaggagcgt 2040
gaagtacgcc tacaacgccg acctgtacaa cgccctgaac gacctgaaca acctggtgat 2100
caccagggac gagaacgaga agctggagta ctacgagaag ttccagatca tcgagaacgt 2160
gttcaagcag aagaagaagc ctaccctgaa gcagatcgcc aaggagatcc tggtgaacga 2220
ggaggacatc aagggctaca gggtgaccag caccggcaag cctgagttca ccaacctgaa 2280
ggtgtaccac gacatcaagg acatcaccgc caggaaggag atcatcgaga acgccgagct 2340
gctggaccag atcgccaaga tcctgaccat ctaccagagc agcgaggaca tccaggagga 2400
gctgaccaac ctgaacagcg agctgaccca ggaggagatc gagcagatca gcaacctgaa 2460
gggctacacc ggcacccaca acctgagcct gaaggccatc aacctgatcc tggacgagct 2520
gtggcacacc aacgacaacc agatcgccat cttcaacagg ctgaagctgg tgcctaagaa 2580
ggtggacctg agccagcaga aggagatccc taccaccctg gtggacgact tcatcctgag 2640
ccctgtggtg aagaggagct tcatccagag catcaaggtg atcaacgcca tcatcaagaa 2700
gtacggcctg cctaacgaca tcatcatcga gctggccagg gagaagaaca gcaaggacgc 2760
ccagaagatg atcaacgaga tgcagaagag gaacaggcag accaacgaga ggatcgagga 2820
gatcatcagg accaccggca aggagaacgc caagtacctg atcgagaaga tcaagctgca 2880
cgacatgcag gagggcaagt gcctgtacag cctggaggcc atccctctgg aggacctgct 2940
gaacaaccct ttcaactacg aggtggacca catcatccct aggagcgtga gcttcgacaa 3000
cagcttcaac aacaaggtgc tggtgaagca ggaggagaac agcaagaagg gcaacaggac 3060
ccctttccag tacctgagca gcagcgacag caagatcagc tacgagacct tcaagaagca 3120
catcctgaac ctggccaagg gcaagggcag gatcagcaag accaagaagg agtacctgct 3180
ggaggagagg gacatcaaca ggttcagcgt gcagaaggac ttcatcaaca ggaacctggt 3240
ggacaccagg tacgccacca ggggcctgat gaacctgctg aggagctact tcagggtgaa 3300
caacctggac gtgaaggtga agagcatcaa cggcggcttc accagcttcc tgaggaggaa 3360
gtggaagttc aagaaggaga ggaacaaggg ctacaagcac cacgccgagg acgccctgat 3420
catcgccaac gccgacttca tcttcaagga gtggaagaag ctggacaagg ccaagaaggt 3480
gatggagaac cagatgttcg aggagaagca ggccgagagc atgcctgaga tcgagaccga 3540
gcaggagtac aaggagatct tcatcacccc tcaccagatc aagcacatca aggacttcaa 3600
ggactacaag tacagccaca gggtggacaa gaagcctaac aggaagctga tcaacgacac 3660
cctgtacagc accaggaagg acgacaaggg caacaccctg atcgtgaaca acctgaacgg 3720
cctgtacgac aaggacaacg acaagctgaa gaagctgatc aacaagagcc ctgagaagct 3780
gctgatgtac caccacgacc ctcagaccta ccagaagctg aagctgatca tggagcagta 3840
cggcgacgag aagaaccctc tgtacaagta ctacgaggag accggcaact acctgaccaa 3900
gtacagcaag aaggacaacg gccctgtgat caagaagatc aagtactacg gcaacaagct 3960
gaacgcccac ctggacatca ccgacgacta ccctaacagc aggaacaagg tggtgaagct 4020
gagcctgaag ccttacaggt tcgacgtgta cctggacaac ggcgtgtaca agttcgtgac 4080
cgtgaagaac ctggacgtga tcaagaagga gaactactac gaggtgaaca gcaagtgcta 4140
cgaggaggcc aagaagctga agaagatcag caaccaggcc gagttcatcg ccagcttcta 4200
caagaacgac ctgatcaaga tcaacggcga gctgtacagg gtgatcggcg tgaacaacga 4260
cctgctgaac aggatcgagg tgaacatgat cgacatcacc tacagggagt acctggagaa 4320
catgaacgac aagaggcctc ctcacatcat caagaccatc gccagcaaga cccagagcat 4380
caagaagtac agcaccgaca tcctgggcaa cctgtacgag gtgaagagca agaagcaccc 4440
tcagatcatc aagaagggcg gcagcagcgg cggcagcacc aacctgagcg acatcatcga 4500
gaaggagacc ggtaagcaac tggttatcca ggaatccatc ctcatgctcc cagaggaggt 4560
ggaagaagtc attgggaaca agccggaaag cgatatactc gtgcacaccg cctacgacga 4620
gagcaccgac gagaatgtca tgcttctgac tagcgacgcc cctgaataca agccttgggc 4680
tctggtcata caggatagca acggtgagaa caagattaag atgctctctg gtggttctcc 4740
caagaagaag aggaaagtcg gatcctaccc atacgatgtt ccagattacg cttacccata 4800
cgatgttcca gattacgctt acccatacga tgttccagat tacgcttaag aattctagca 4860
ataaaggatc gtttattttc attggaagcg tgtgttggtt ttttgatcag gcgcggcggc 4920
cgcaggaacc cctagtgatg gagttggcca ctccctctct gcgcgctcgc tcgctcactg 4980
aggccgggcg accaaaggtc gcccgacgcc cgggctttgc ccgggcggcc tcagtgagcg 5040
agcgagcgcg cagctgcctg caggggcgcc tgatgcggta ttttctcctt acgcatctgt 5100
gcggtatttc acaccgcata cgtcaaagca accatagtac gcgccctgta gcggcgcatt 5160
aagcgcggcg ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccttagc 5220
gcccgctcct ttcgctttct tcccttcctt tctcgccacg ttcgccggct ttccccgtca 5280
agctctaaat cgggggctcc ctttagggtt ccgatttagt gctttacggc acctcgaccc 5340
caaaaaactt gatttgggtg atggttcacg tagtgggcca tcgccctgat agacggtttt 5400
tcgccctttg acgttggagt ccacgttctt taatagtgga ctcttgttcc aaactggaac 5460
aacactcaac tctatctcgg gctattcttt tgatttataa gggattttgc cgatttcggt 5520
ctattggtta aaaaatgagc tgatttaaca aaaatttaac gcgaatttta acaaaatatt 5580
aacgtttaca attttatggt gcactctcag tacaatctgc tctgatgccg catagttaag 5640
ccagccccga cacccgccaa cacccgctga cgcgccctga cgggcttgtc tgctcccggc 5700
atccgcttac agacaagctg tgaccgtctc cgggagctgc atgtgtcaga ggttttcacc 5760
gtcatcaccg aaacgcgcga gacgaaaggg cctcgtgata cgcctatttt tataggttaa 5820
tgtcatgata ataatggttt cttagacgtc aggtggcact tttcggggaa atgtgcgcgg 5880
aacccctatt tgtttatttt tctaaataca ttcaaatatg tatccgctca tgagacaata 5940
accctgataa atgcttcaat aatattgaaa aaggaagagt atgagtattc aacatttccg 6000
tgtcgccctt attccctttt ttgcggcatt ttgccttcct gtttttgctc acccagaaac 6060
gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca cgagtgggtt acatcgaact 6120
ggatctcaac agcggtaaga tccttgagag ttttcgcccc gaagaacgtt ttccaatgat 6180
gagcactttt aaagttctgc tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga 6240
gcaactcggt cgccgcatac actattctca gaatgacttg gttgagtact caccagtcac 6300
agaaaagcat cttacggatg gcatgacagt aagagaatta tgcagtgctg ccataaccat 6360
gagtgataac actgcggcca acttacttct gacaacgatc ggaggaccga aggagctaac 6420
cgcttttttg cacaacatgg gggatcatgt aactcgcctt gatcgttggg aaccggagct 6480
gaatgaagcc ataccaaacg acgagcgtga caccacgatg cctgtagcaa tggcaacaac 6540
gttgcgcaaa ctattaactg gcgaactact tactctagct tcccggcaac aattaataga 6600
ctggatggag gcggataaag ttgcaggacc acttctgcgc tcggcccttc cggctggctg 6660
gtttattgct gataaatctg gagccggtga gcgtggaagc cgcggtatca ttgcagcact 6720
ggggccagat ggtaagccct cccgtatcgt agttatctac acgacgggga gtcaggcaac 6780
tatggatgaa cgaaatagac agatcgctga gataggtgcc tcactgatta agcattggta 6840
actgtcagac caagtttact catatatact ttagattgat ttaaaacttc atttttaatt 6900
taaaaggatc taggtgaaga tcctttttga taatctcatg accaaaatcc cttaacgtga 6960
gttttcgttc cactgagcgt cagaccccgt agaaaagatc aaaggatctt cttgagatcc 7020
tttttttctg cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt 7080
ttgtttgccg gatcaagagc taccaactct ttttccgaag gtaactggct tcagcagagc 7140
gcagatacca aatactgttc ttctagtgta gccgtagtta ggccaccact tcaagaactc 7200
tgtagcaccg cctacatacc tcgctctgct aatcctgtta ccagtggctg ctgccagtgg 7260
cgataagtcg tgtcttaccg ggttggactc aagacgatag ttaccggata aggcgcagcg 7320
gtcgggctga acggggggtt cgtgcacaca gcccagcttg gagcgaacga cctacaccga 7380
actgagatac ctacagcgtg agctatgaga aagcgccacg cttcccgaag ggagaaaggc 7440
ggacaggtat ccggtaagcg gcagggtcgg aacaggagag cgcacgaggg agcttccagg 7500
gggaaacgcc tggtatcttt atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg 7560
atttttgtga tgctcgtcag gggggcggag cctatggaaa aacgccagca acgcggcctt 7620
tttacggttc ctggcctttt gctggccttt tgctcacatg t 7661
<210> 4
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
cattattttt ctgtaagacc 20
<210> 5
<211> 5895
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg ggcgaccttt 60
ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa ctccatcact 120
aggggttcct gcggcctcta gactcgagga gggcctattt cccatgattc cttcatattt 180
gcatatacga tacaaggctg ttagagagat aattagaatt aatttgactg taaacacaaa 240
gatattagta caaaatacgt gacgtagaaa gtaataattt cttgggtagt ttgcagtttt 300
aaaattatgt tttaaaatgg actatcatat gcttaccgta acttgaaagt atttcgattt 360
cttggcttta tatatcttgt ggaaaggacg aaacaccgca ttatttttct gtaagaccgt 420
tatagtactc tggaaacaga atctactata acaaggcaaa atgccgtgtt tatctcgtca 480
acttgttggc gagatttttt ttttttttct agacccagct ttcttgtaca aagttggcat 540
tagctagcgc taaccggtgg cgcgttaagt cgacgaacgc tgacgtcatc aacccgctcc 600
aaggaatcgc gggcccagtg tcactaggcg ggaacaccca gcgcgcgtgc gccctggcag 660
gaagatggct gtgagggaca ggggagtggc gccctgcaat atttgcatgt cgctatgtgt 720
tctgggaaat caccataaac gtgaaatgtc tttggatttg ggaatcttat aagttctgta 780
tgagaccaca gatctgacat tatttttctg taagaccgtt atagtactct ggaaacagaa 840
tctactataa caaggcaaaa tgccgtgttt atctcgtcaa cttgttggcg agattttttt 900
tttttctaga cccagctttc ttgtacaaag ttggcattaa agcttatcga taccctgcag 960
tatttagcat gccccaccca tctgcaaggc attctggata gtgtcaaaac agccggaaat 1020
caagtccgtt tatctcaaac tttagcattt tgggaataaa tgatatttgc tatgctggtt 1080
aaattagatt ttagttaaat ttcctgctga agctctagta cgataagtaa cttgacctaa 1140
gtgtaaagtt gagatttcct tcaggtttat atagcttgtg cgccgcctgg gtaccagatc 1200
tgacattatt tttctgtaag accgttatag tactctggaa acagaatcta ctataacaag 1260
gcaaaatgcc gtgtttatct cgtcaacttg ttggcgagat tttttttttt ttctagaccc 1320
agctttcggt actcgcggcc gccggccgtc cgccctcggc accattcctc acgacaccga 1380
aatatggcga cgggtgagga atggtgggga gttattttta gagcggtgag gaatggtggg 1440
caggcagcag gtgttggggg agttattttt agagcgggga gttattttta gagcggtgag 1500
gaatggtgga caccgaaata tggcgacggg tgaggaatgg tgccgtcgcc atatttgggt 1560
gtcccgtccg ccctcggccg gggccgcatt cctgggggcc gggcggtgct cccgcccgcc 1620
tcgataaaag gctccggggc cggcggcggc ccacgagcta cccggaggag cgggaggcgt 1680
ctctgccagc ggtccgacgc gcagtcagca ccaggtaggt gggcaccgcg ccgtgccgtg 1740
ccctctggct aactaccatg gtgagcaagg gcgaggagct gttcaccggg gtggtgccca 1800
tcctggtcga gctggacggc gacgtaaacg gccacaagtt cagcgtgtct ggcgagggcg 1860
agggcgatgc cacctacggc aagctgaccc tgaagttcat ctgcaccacc ggcaagctgc 1920
ccgtgccctg gcccaccctc gtgaccaccc tgacctacgg cgtgcagtgc ttcagccgct 1980
accccgacca catgaagcag cacgacttct tcaagtccgc catgcccgaa ggctacgtcc 2040
aggagcgcac catcttcttc aaggacgacg gcaactacaa gacccgcgcc gaggtgaagt 2100
tcgagggcga caccctggtg aaccgcatcg agctgaaggg catcgacttc aaggaggacg 2160
gcaacatcct ggggcacaag ctggagtaca actacaacag ccacaacgtc tatatcatgg 2220
ccgacaagca gaagaacggc atcaaggcga acttcaagat ccgccacaac atcgaggacg 2280
gcagcgtgca gctcgccgac cactaccagc agaacacccc catcggcgac ggccccgtgc 2340
tgctgcccga caaccactac ctgagcaccc agtccgccct gagcaaagac cccaacgaga 2400
agcgcgatca catggtcctg ctggagttcg tgaccgccgc cgggatcact ctcggcatgg 2460
acgagctgta caagtgcgca acaaacttct ctctgctgaa acaagccgga gatgtcgaag 2520
agaatcctgg acccactaat ctgtcagata ttattgaaaa ggagaccggt aagcaactgg 2580
ttatccagga atccatcctc atgctcccag aggaggtgga agaagtcatt gggaacaagc 2640
cggaaagcga tatactcgtg cacaccgcct acgacgagag caccgacgag aatgtcatgc 2700
ttctgactag cgacgcccct gaatacaagc cttgggctct ggtcatacag gatagcaacg 2760
gtgagaacaa gattaagatg ctctctggtg gttctcccaa gaagaagagg aaagtcggat 2820
cctacccata cgatgttcca gattacgctt acccatacga tgttccagat tacgcttacc 2880
catacgatgt tccagattac gcttaagaat tcctagagct cgctgatcag cctcgactgt 2940
gccttctagt tgccagccat ctgttgtttg cccctccccc gtgccttcct tgaccctgga 3000
aggtgccact cccactgtcc tttcctaata aaatgaggaa attgcatcgc attgtctgag 3060
taggtgtcat tctattctgg ggggtggggt ggggcaggac agcaaggggg aggattggga 3120
agagaatagc aggcatgctg gggaggaatt cggccgcagg aacccctagt gatggagttg 3180
gccactccct ctctgcgcgc tcgctcgctc actgaggccg ggcgaccaaa ggtcgcccga 3240
cgcccgggct ttgcccgggc ggcctcagtg agcgagcgag cgcgcagctg cctgcagggg 3300
cgcctgatgc ggtattttct ccttacgcat ctgtgcggta tttcacaccg catacgtcaa 3360
agcaaccata gtacgcgccc tgtagcggcg cattaagcgc ggcgggtgtg gtggttacgc 3420
gcagcgtgac cgctacactt gccagcgcct tagcgcccgc tcctttcgct ttcttccctt 3480
cctttctcgc cacgttcgcc ggctttcccc gtcaagctct aaatcggggg ctccctttag 3540
ggttccgatt tagtgcttta cggcacctcg accccaaaaa acttgatttg ggtgatggtt 3600
cacgtagtgg gccatcgccc tgatagacgg tttttcgccc tttgacgttg gagtccacgt 3660
tctttaatag tggactcttg ttccaaactg gaacaacact caactctatc tcgggctatt 3720
cttttgattt ataagggatt ttgccgattt cggtctattg gttaaaaaat gagctgattt 3780
aacaaaaatt taacgcgaat tttaacaaaa tattaacgtt tacaatttta tggtgcactc 3840
tcagtacaat ctgctctgat gccgcatagt taagccagcc ccgacacccg ccaacacccg 3900
ctgacgcgcc ctgacgggct tgtctgctcc cggcatccgc ttacagacaa gctgtgaccg 3960
tctccgggag ctgcatgtgt cagaggtttt caccgtcatc accgaaacgc gcgagacgaa 4020
agggcctcgt gatacgccta tttttatagg ttaatgtcat gataataatg gtttcttaga 4080
cgtcaggtgg cacttttcgg ggaaatgtgc gcggaacccc tatttgttta tttttctaaa 4140
tacattcaaa tatgtatccg ctcatgagac aataaccctg ataaatgctt caataatatt 4200
gaaaaaggaa gagtatgagt attcaacatt tccgtgtcgc ccttattccc ttttttgcgg 4260
cattttgcct tcctgttttt gctcacccag aaacgctggt gaaagtaaaa gatgctgaag 4320
atcagttggg tgcacgagtg ggttacatcg aactggatct caacagcggt aagatccttg 4380
agagttttcg ccccgaagaa cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg 4440
gcgcggtatt atcccgtatt gacgccgggc aagagcaact cggtcgccgc atacactatt 4500
ctcagaatga cttggttgag tactcaccag tcacagaaaa gcatcttacg gatggcatga 4560
cagtaagaga attatgcagt gctgccataa ccatgagtga taacactgcg gccaacttac 4620
ttctgacaac gatcggagga ccgaaggagc taaccgcttt tttgcacaac atgggggatc 4680
atgtaactcg ccttgatcgt tgggaaccgg agctgaatga agccatacca aacgacgagc 4740
gtgacaccac gatgcctgta gcaatggcaa caacgttgcg caaactatta actggcgaac 4800
tacttactct agcttcccgg caacaattaa tagactggat ggaggcggat aaagttgcag 4860
gaccacttct gcgctcggcc cttccggctg gctggtttat tgctgataaa tctggagccg 4920
gtgagcgtgg aagccgcggt atcattgcag cactggggcc agatggtaag ccctcccgta 4980
tcgtagttat ctacacgacg gggagtcagg caactatgga tgaacgaaat agacagatcg 5040
ctgagatagg tgcctcactg attaagcatt ggtaactgtc agaccaagtt tactcatata 5100
tactttagat tgatttaaaa cttcattttt aatttaaaag gatctaggtg aagatccttt 5160
ttgataatct catgaccaaa atcccttaac gtgagttttc gttccactga gcgtcagacc 5220
ccgtagaaaa gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct 5280
tgcaaacaaa aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa 5340
ctctttttcc gaaggtaact ggcttcagca gagcgcagat accaaatact gttcttctag 5400
tgtagccgta gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc 5460
tgctaatcct gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttgg 5520
actcaagacg atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca 5580
cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat 5640
gagaaagcgc cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg 5700
tcggaacagg agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc 5760
ctgtcgggtt tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc 5820
ggagcctatg gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc 5880
cttttgctca catgt 5895
<210> 6
<211> 5067
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
gcggcctcta gactcgagcg gccgtccgcc ctcggcacca ttcctcacga caccgaaata 60
tggcgacggg tgaggaatgg tggggagtta tttttagagc ggtgaggaat ggtgggcagg 120
cagcaggtgt tgggggagtt atttttagag cggggagtta tttttagagc ggtgaggaat 180
ggtggacacc gaaatatggc gacgggtgag gaatggtgcc gtcgccatat ttgggtgtcc 240
cgtccgccct cggccggggc cgcattcctg ggggccgggc ggtgctcccg cccgcctcga 300
taaaaggctc cggggccggc ggcggcccac gagctacccg gaggagcggg aggcgtctct 360
gccagcggtc cgacgcgcag tcagcaccag gtaggtgggc accgcgccgt gccgtgccgc 420
tagctaatac gactcactat agggagagcc gccaccatgg actataagga ccacgacgga 480
gactacaagg atcatgatat tgattacaaa gacgatgacg ataagatggc cccaaagaag 540
aagcggaagg tcggtatcca cggagtccca gcagccatgg acagcctctt gatgaaccgg 600
agggagtttc tttaccaatt caaaaatgtc cgctgggcta agggtcggcg tgagacctac 660
ctgtgctacg tagtgaagag gcgtgacagt gctacatcct tttcactgga ctttggttat 720
cttcgcaata agaacggctg ccacgtggaa ttgctcttcc tccgctacat ctcggactgg 780
gacctagacc ctggccgctg ctaccgcgtc acctggttca tctcctggag cccctgctac 840
gactgtgccc gacatgtggc cgactttctg cgagggaacc ccaacctcag tctgaggatc 900
ttcaccgcgc gcctctactt ctgtgaggac cgcaaggctg agcccgaggg gctgcggcgg 960
ctgcaccgcg ccggggtgca aatagccatc atgaccttca aagattattt ttactgctgg 1020
aatacttttg tagaaaacca tggaagaact ttcaaagcct gggaagggct gcatgaaaat 1080
tcagttcgtc tatccagaca gcttcggcgc atccttttgc ccagcggcag cgagactccc 1140
gggacctcag agtccgccac acccgaaagc ggcaagagga actacatcct gggcctggcc 1200
atcggcatca ccagcgtggg ctacggcatc atcgactacg agaccaggga cgtgatcgac 1260
gccggcgtga ggctgttcaa ggaggccaac gtggagaaca acgagggcag gaggagcaag 1320
aggggcgcca ggaggctgaa gaggaggagg aggcacagga tccagagggt gaagaagctg 1380
ctgttcgact acaacctgct gaccgaccac agcgagctga gcggcatcaa cccttacgag 1440
gccagggtga agggcctgag ccagaagctg agcgaggagg agttcagcgc cgccctgctg 1500
cacctggcca agaggagggg cgtgcacaac gtgaacgagg tggaggagga caccggcaac 1560
gagctgagca ccaaggagca gatcagcagg aacagcaagg ccctggagga gaagtacgtg 1620
gccgagctgc agctggagag gctgaagaag gacggcgagg tgaggggcag catcaacagg 1680
ttcaagacca gcgactacgt gaaggaggcc aagcagctgc tgaaggtgca gaaggcctac 1740
caccagctgg accagagctt catcgacacc tacatcgacc tgctggagac caggaggacc 1800
tactacgagg gccctggcga gggcagccct ttcggctgga aggacatcaa ggagtggtac 1860
gagatgctga tgggccactg cacctacttc cctgaggagc tgaggagcgt gaagtacgcc 1920
tacaacgccg acctgtacaa cgccctgaac gacctgaaca acctggtgat caccagggac 1980
gagaacgaga agctggagta ctacgagaag ttccagatca tcgagaacgt gttcaagcag 2040
aagaagaagc ctaccctgaa gcagatcgcc aaggagatcc tggtgaacga ggaggacatc 2100
aagggctaca gggtgaccag caccggcaag cctgagttca ccaacctgaa ggtgtaccac 2160
gacatcaagg acatcaccgc caggaaggag atcatcgaga acgccgagct gctggaccag 2220
atcgccaaga tcctgaccat ctaccagagc agcgaggaca tccaggagga gctgaccaac 2280
ctgaacagcg agctgaccca ggaggagatc gagcagatca gcaacctgaa gggctacacc 2340
ggcacccaca acctgagcct gaaggccatc aacctgatcc tggacgagct gtggcacacc 2400
aacgacaacc agatcgccat cttcaacagg ctgaagctgg tgcctaagaa ggtggacctg 2460
agccagcaga aggagatccc taccaccctg gtggacgact tcatcctgag ccctgtggtg 2520
aagaggagct tcatccagag catcaaggtg atcaacgcca tcatcaagaa gtacggcctg 2580
cctaacgaca tcatcatcga gctggccagg gagaagaaca gcaaggacgc ccagaagatg 2640
atcaacgaga tgcagaagag gaacaggcag accaacgaga ggatcgagga gatcatcagg 2700
accaccggca aggagaacgc caagtacctg atcgagaaga tcaagctgca cgacatgcag 2760
gagggcaagt gcctgtacag cctggaggcc atccctctgg aggacctgct gaacaaccct 2820
ttcaactacg aggtggacca catcatccct aggagcgtga gcttcgacaa cagcttcaac 2880
aacaaggtgc tggtgaagca ggaggagaac agcaagaagg gcaacaggac ccctttccag 2940
tacctgagca gcagcgacag caagatcagc tacgagacct tcaagaagca catcctgaac 3000
ctggccaagg gcaagggcag gatcagcaag accaagaagg agtacctgct ggaggagagg 3060
gacatcaaca ggttcagcgt gcagaaggac ttcatcaaca ggaacctggt ggacaccagg 3120
tacgccacca ggggcctgat gaacctgctg aggagctact tcagggtgaa caacctggac 3180
gtgaaggtga agagcatcaa cggcggcttc accagcttcc tgaggaggaa gtggaagttc 3240
aagaaggaga ggaacaaggg ctacaagcac cacgccgagg acgccctgat catcgccaac 3300
gccgacttca tcttcaagga gtggaagaag ctggacaagg ccaagaaggt gatggagaac 3360
cagatgttcg aggagaagca ggccgagagc atgcctgaga tcgagaccga gcaggagtac 3420
aaggagatct tcatcacccc tcaccagatc aagcacatca aggacttcaa ggactacaag 3480
tacagccaca gggtggacaa gaagcctaac aggaagctga tcaacgacac cctgtacagc 3540
accaggaagg acgacaaggg caacaccctg atcgtgaaca acctgaacgg cctgtacgac 3600
aaggacaacg acaagctgaa gaagctgatc aacaagagcc ctgagaagct gctgatgtac 3660
caccacgacc ctcagaccta ccagaagctg aagctgatca tggagcagta cggcgacgag 3720
aagaaccctc tgtacaagta ctacgaggag accggcaact acctgaccaa gtacagcaag 3780
aaggacaacg gccctgtgat caagaagatc aagtactacg gcaacaagct gaacgcccac 3840
ctggacatca ccgacgacta ccctaacagc aggaacaagg tggtgaagct gagcctgaag 3900
ccttacaggt tcgacgtgta cctggacaac ggcgtgtaca agttcgtgac cgtgaagaac 3960
ctggacgtga tcaagaagga gaactactac gaggtgaaca gcaagtgcta cgaggaggcc 4020
aagaagctga agaagatcag caaccaggcc gagttcatcg ccagcttcta caagaacgac 4080
ctgatcaaga tcaacggcga gctgtacagg gtgatcggcg tgaacaacga cctgctgaac 4140
aggatcgagg tgaacatgat cgacatcacc tacagggagt acctggagaa catgaacgac 4200
aagaggcctc ctcacatcat caagaccatc gccagcaaga cccagagcat caagaagtac 4260
agcaccgaca tcctgggcaa cctgtacgag gtgaagagca agaagcaccc tcagatcatc 4320
aagaagggcg gcagcagcgg cggcagcacc aacctgagcg acatcatcga gaaggagacc 4380
ggtaagcaac tggttatcca ggaatccatc ctcatgctcc cagaggaggt ggaagaagtc 4440
attgggaaca agccggaaag cgatatactc gtgcacaccg cctacgacga gagcaccgac 4500
gagaatgtca tgcttctgac tagcgacgcc cctgaataca agccttgggc tctggtcata 4560
caggatagca acggtgagaa caagattaag atgctctctg gtggttctcc caagaagaag 4620
aggaaagtct aatagcaata aaggatcgtt tattttcatt ggaagcgtgt gttggttttt 4680
tgatcaggcg cggagggcct atttcccatg attccttcat atttgcatat acgatacaag 4740
gctgttagag agataattag aattaatttg actgtaaaca caaagatatt agtacaaaat 4800
acgtgacgta gaaagtaata atttcttggg tagtttgcag ttttaaaatt atgttttaaa 4860
atggactatc atatgcttac cgtaacttga aagtatttcg atttcttggc tttatatatc 4920
ttgtggaaag gacgaaacac cgcattattt ttctgtaaga ccgttatagt actctggaaa 4980
cagaatctac tataacaagg caaaatgccg tgtttatctc gtcaacttgt tggcgagatt 5040
tttttttttt ttctagaccg cggccgc 5067
<210> 7
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
acttacaggc tccaatagtg 20
<210> 8
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
gtaacagtct gagtaggagc 20
<210> 9
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
tgtgtcacca gagtaacagt 20
<210> 10
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
gtaaccacag gttgtgtcac 20
<210> 11
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
gctcctactc agactgttac 20
<210> 12
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
gttactctgg tgacacaacc 20
<210> 13
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
tggcagtttc cttagtaacc 20
<210> 14
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 14
caggtacctc caacatcaag 20
<210> 15
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 15
gaaactgcca tctccaaact 20
<210> 16
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 16
tgatcaagca gagaaagcca 20
<210> 17
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 17
aacttgatca agcagagaaa 20
<210> 18
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 18
aaggtatgag aaaaaatgat 20
<210> 19
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 19
acaggttgtg tcaccagagt 20
<210> 20
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 20
aacgagatga tcatcaagca 20
<210> 21
<211> 30
<212> DNA
<213> Homo sapiens
<400> 21
ctgttactct ggtgacacaa cctgtggtta 30
<210> 22
<211> 30
<212> DNA
<213> Homo sapiens
<400> 22
agactgttac tctggtgaca caacctgtgg 30
<210> 23
<211> 30
<212> DNA
<213> Homo sapiens
<400> 23
tcttccttga tgttggaggt acctgctctg 30
<210> 24
<211> 30
<212> DNA
<213> Homo sapiens
<400> 24
atatcaacga gatgatcatc aagcagaagg 30

Claims (8)

1.一种靶向杜氏肌营养不良症相关的外显子剪接增强子的sgRNA,其特征在于,所述外显子剪接增强子为靶向人类DMD基因Exon51的外显子剪接增强子元件,所述外显子剪接增强子元件的核苷酸序列包括:
针对人类DMD基因Exon51的sgRNA-12,核苷酸序列如SEQ ID NO.19所示;和针对人类DMD基因Exon51的sgRNA-13,核苷酸序列如SEQ ID NO.20所示。
2.一种权利要求1所述sgRNA在制备治疗杜氏肌营养不良症的药物中的应用。
3.一种杜氏肌营养不良症相关的基因编辑工具,其特征在于,包括胞嘧啶脱氨酶和Cas9突变体的融合蛋白、权利要求1所述sgRNA和载体。
4.根据权利要求3所述的基因编辑工具,其特征在于,所述胞嘧啶脱氨酶为AID,AID和Cas9突变体的融合蛋白的氨基酸序列以及核酸序列分别如SEQ ID NO.1和SEQ ID NO.2所示。
5.根据权利要求3所述的基因编辑工具,其特征在于,所述基因编辑工具由腺相关病毒载体AAV包装。
6.根据权利要求5所述的基因编辑工具,其特征在于,所述腺相关病毒载体AAV的启动子为Syn100启动子或基于ck8a、mhck7设计的启动子。
7.根据权利要求5所述的基因编辑工具,其特征在于,腺相关病毒载体AAV的核苷酸序列如SEQ ID NO.3所示。
8.一种权利要求3-7任一项所述基因编辑工具在制备治疗杜氏肌营养不良症的药物中的应用。
CN202010909759.7A 2020-09-02 2020-09-02 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用 Active CN112063621B (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN202010909759.7A CN112063621B (zh) 2020-09-02 2020-09-02 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用
CN202210530367.9A CN115011598A (zh) 2020-09-02 2020-09-02 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用
EP20952118.6A EP4209590A1 (en) 2020-09-02 2020-09-30 Duchenne muscular dystrophy-related exonic splicing enhancer, sgrna and gene editing tool, and applications
JP2023515078A JP2023540555A (ja) 2020-09-02 2020-09-30 デュシェンヌ型筋ジストロフィーに関連するエクソンスプライシングエンハンサー、sgRNA、遺伝子編集ツールおよび使用
PCT/CN2020/119361 WO2022047876A1 (zh) 2020-09-02 2020-09-30 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用
US18/043,874 US20230287419A1 (en) 2020-09-02 2020-09-30 DUCHENNE MUSCULAR DYSTROPHY-RELATED EXONIC SPLICING ENHANCER, sgRNA AND GENE EDITING TOOL, AND APPLICATIONS
CA3191505A CA3191505A1 (en) 2020-09-02 2020-09-30 Duchenne muscular dystrophy-related exonic splicing enhancer, sgrna and gene editing tool, and applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010909759.7A CN112063621B (zh) 2020-09-02 2020-09-02 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210530367.9A Division CN115011598A (zh) 2020-09-02 2020-09-02 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用

Publications (2)

Publication Number Publication Date
CN112063621A CN112063621A (zh) 2020-12-11
CN112063621B true CN112063621B (zh) 2022-06-28

Family

ID=73666651

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210530367.9A Pending CN115011598A (zh) 2020-09-02 2020-09-02 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用
CN202010909759.7A Active CN112063621B (zh) 2020-09-02 2020-09-02 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210530367.9A Pending CN115011598A (zh) 2020-09-02 2020-09-02 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用

Country Status (6)

Country Link
US (1) US20230287419A1 (zh)
EP (1) EP4209590A1 (zh)
JP (1) JP2023540555A (zh)
CN (2) CN115011598A (zh)
CA (1) CA3191505A1 (zh)
WO (1) WO2022047876A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110499333A (zh) * 2019-08-01 2019-11-26 广州德赫生物科技有限公司 用于修复dmd基因突变的核酸序列及系统
CN112522256B (zh) * 2020-08-19 2023-08-22 南京启真基因工程有限公司 CRISPR/Cas9系统及其在构建抗肌萎缩蛋白基因缺陷的猪源重组细胞中的应用
WO2022204476A1 (en) * 2021-03-26 2022-09-29 The Board Of Regents Of The University Of Texas System Nucleotide editing to reframe dmd transcripts by base editing and prime editing
WO2023039444A2 (en) * 2021-09-08 2023-03-16 Vertex Pharmaceuticals Incorporated Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
US20230348909A1 (en) * 2022-03-30 2023-11-02 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
WO2023206088A1 (en) * 2022-04-26 2023-11-02 Huigene Therapeutics Co., Ltd. Rna base editor for treating dmd-associated diseases
CN115806989B (zh) * 2022-11-25 2023-08-08 昆明理工大学 针对DMD基因5号外显子突变的sgRNA及载体和应用
CN116536255B (zh) * 2023-07-05 2023-09-12 夏同生物科技(苏州)有限公司 一种高效诱导肌肉干细胞的培养基及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727355B2 (en) * 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
EP2119783A1 (en) * 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
AU2013212758A1 (en) * 2012-01-27 2014-08-14 Biomarin Technologies B.V. RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy
AU2014274840B2 (en) * 2013-06-05 2020-03-12 Duke University RNA-guided gene editing and gene regulation
CA2959130A1 (en) * 2014-08-11 2016-02-18 The Board Of Regents Of The University Of Texas System Prevention of muscular dystrophy by crispr/cas9-mediated gene editing
JOP20190166A1 (ar) * 2017-01-05 2019-07-02 Univ Texas استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
EP3712272A4 (en) * 2017-07-25 2021-10-13 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences METHOD FOR MODULATION OF RNA SPLICE BY INDUCTION OF A BASE MUTATION AT THE SPLICE POINT OR A BASE SUBSTITUTION IN THE POLYPYRIMIDINE REGION
CN110760511B (zh) * 2018-07-27 2021-09-07 广东赤萌医疗科技有限公司 一种用于治疗杜氏肌营养不良症的gRNA、表达载体、CRISPR-Cas9系统

Also Published As

Publication number Publication date
EP4209590A1 (en) 2023-07-12
JP2023540555A (ja) 2023-09-25
CA3191505A1 (en) 2022-03-10
US20230287419A1 (en) 2023-09-14
CN115011598A (zh) 2022-09-06
WO2022047876A1 (zh) 2022-03-10
CN112063621A (zh) 2020-12-11

Similar Documents

Publication Publication Date Title
CN112063621B (zh) 杜氏肌营养不良症相关的外显子剪接增强子、sgRNA、基因编辑工具及应用
CN108359691B (zh) 利用mito-CRISPR/Cas9系统敲除异常线粒体DNA的试剂盒及方法
US20210145940A1 (en) Dystrophin gene exon deletion using engineered nucleases
CN110446781A (zh) 供体修复模板多重基因组编辑
US20200283807A1 (en) Method and cell line for production of phytocannabinoids and phytocannabinoid analogues in yeast
US20190185850A1 (en) Single guide rna/crispr/cas9 systems, and methods of use thereof
CN101213203A (zh) 在转录后水平调节核酸表达的方法和组合物
DK2718440T3 (en) NUCLEASE ACTIVITY PROTEIN, FUSION PROTEINS AND APPLICATIONS THEREOF
KR102528337B1 (ko) 정의된 서열 및 길이의 dna 단일 가닥 분자의 확장 가능한 생명공학적 생산
CN112153990A (zh) 用于常染色体显性疾病的基因编辑
KR20210044795A (ko) 고 처리량 대사 공학에서 CRISPRi의 응용
KR20140099224A (ko) 케토-아이소발레레이트 데카르복실라제 효소 및 이의 이용 방법
CN112725282A (zh) 携带正交tRNA/氨酰tRNA合成酶的稳定细胞系的构建
KR20140092759A (ko) 숙주 세포 및 아이소부탄올의 제조 방법
US20040003420A1 (en) Modified recombinase
CN114934031B (zh) 新型Cas效应蛋白、基因编辑系统及用途
CN112251464B (zh) 一种基因点突变的诱导方法
KR20220003553A (ko) 레트 증후군의 치료에 유용한 조성물
CN114634923B (zh) 腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途
CN110914414A (zh) 利用设计dna重组酶遗传改变基因组的方法与手段
CN113166779A (zh) 调控的基因编辑系统
CN109295100A (zh) 携带正交tRNA/氨酰tRNA合成酶的稳定细胞系的构建
US6376192B1 (en) Method for screening of DNA libraries and generation of recombinant DNA constructs
KR101845739B1 (ko) 신규한 암용해 바이러스, 이의 제작 방법 및 이의 용도
CN114958760B (zh) 一种构建阿尔兹海默症模型猪的基因编辑技术及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant